58 related articles for article (PubMed ID: 36563515)
1. Design, synthesis, and biological evaluation of BRD4 degraders.
Ding M; Shao Y; Sun D; Meng S; Zang Y; Zhou Y; Li J; Lu W; Zhu S
Bioorg Med Chem; 2023 Jan; 78():117134. PubMed ID: 36563515
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics.
Ma Z; Bolinger AA; Zhou J; Tian B
Expert Opin Ther Targets; 2023 Jan; 27(1):1-7. PubMed ID: 36710583
[TBL] [Abstract][Full Text] [Related]
3. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma.
Das D; Leung JY; Balamurugan S; Tergaonkar V; Loh AHP; Chiang CM; Taneja R
EMBO Rep; 2024 Feb; 25(2):832-852. PubMed ID: 38191874
[TBL] [Abstract][Full Text] [Related]
4. A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer.
Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
[TBL] [Abstract][Full Text] [Related]
5. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
6. BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review.
Zhang M; Li Y; Zhang Z; Zhang X; Wang W; Song X; Zhang D
Curr Drug Targets; 2023; 24(14):1079-1092. PubMed ID: 37846578
[TBL] [Abstract][Full Text] [Related]
7. Targeting Brd4 for cancer therapy: inhibitors and degraders.
Duan Y; Guan Y; Qin W; Zhai X; Yu B; Liu H
Medchemcomm; 2018 Nov; 9(11):1779-1802. PubMed ID: 30542529
[TBL] [Abstract][Full Text] [Related]
8. Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development.
Yan L; Tan S; Wang H; Yuan H; Liu X; Chen Y; de Thé H; Zhu J; Zhou J
Leukemia; 2024 Apr; 38(4):851-864. PubMed ID: 38326409
[TBL] [Abstract][Full Text] [Related]
9. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K; Samur MK; Liow P; Wen K; Yamamoto L; Liu J; Morelli E; Gulla A; Tai YT; Qi J; Hideshima T; Anderson KC
Clin Cancer Res; 2023 May; 29(9):1807-1821. PubMed ID: 36780189
[TBL] [Abstract][Full Text] [Related]
10. Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.
Li YD; Ma MW; Hassan MM; Hunkeler M; Teng M; Puvar K; Lumpkin R; Sandoval B; Jin CY; Ficarro SB; Wang MY; Xu S; Groendyke BJ; Sigua LH; Tavares I; Zou C; Tsai JM; Park PMC; Yoon H; Majewski FC; Marto JA; Qi J; Nowak RP; Donovan KA; Słabicki M; Gray NS; Fischer ES; Ebert BL
bioRxiv; 2023 Feb; ():. PubMed ID: 36824856
[TBL] [Abstract][Full Text] [Related]
11. A BRD4-Targeting Photothermal Agent for Controlled Protein Degradation.
Shi M; Li Y; Pan W; Fu Z; Wang K; Liu X; Li N; Tang B
Angew Chem Int Ed Engl; 2024 May; ():e202403258. PubMed ID: 38721770
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of sulfonamide derivatives targeting EGFR
Cao L; Yao H; Yu L; Ren Y; Liu J; Li X; Jia X
Bioorg Med Chem; 2023 May; 85():117241. PubMed ID: 37087886
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and bioactivity evaluations of 8-substituted-quinoline-2-carboxamide derivatives as novel histone deacetylase (HDAC) inhibitors.
Zhao Y; Yao Z; Ren W; Yang X; Hou X; Cao S; Fang H
Bioorg Med Chem; 2023 May; 85():117242. PubMed ID: 37079967
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
15. Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids.
Liu P; Cheng M; Guo J; Cao D; Luo J; Wan Y; Fang Y; Jin Y; Xie SS; Liu J
Bioorg Med Chem; 2023 Jan; 78():117146. PubMed ID: 36580744
[TBL] [Abstract][Full Text] [Related]
16. Neuritogenic steroid glycosides from crown-of-thorns starfish: Possible involvement of p38 mitogen-activated protein kinase and attenuation of cognitive impairment in senescence-accelerated mice (SAMP8) by peripheral administration.
Sasayama Y; Mamiya T; Qi J; Shibata T; Uchida K; Nabeshima T; Ojika M
Bioorg Med Chem; 2023 Jan; 78():117144. PubMed ID: 36577328
[TBL] [Abstract][Full Text] [Related]
17. Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticles.
Dong S; Wang J; Guo Z; Zhang Y; Zha W; Wang Y; Liu C; Xing H; Li X
Bioorg Med Chem; 2023 Jan; 78():117135. PubMed ID: 36577327
[TBL] [Abstract][Full Text] [Related]
18. Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines.
Yan Z; Lyu X; Lin D; Wu G; Gong Y; Ren X; Xiao J; Lou J; Huang H; Chen Y; Zhao Y
Eur J Med Chem; 2023 Jun; 254():115381. PubMed ID: 37084596
[TBL] [Abstract][Full Text] [Related]
19. Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.
Scherbakov AM; Sorokin DV; Razuvaeva VE; Shchegolev YY; Andreeva OE; Salnikova DI; Fetisov TI; Vlasova OA; Kirsanov KI; Gudkova MV; Krasil'nikov MA
Biomed Rep; 2024 Mar; 20(3):42. PubMed ID: 38343657
[TBL] [Abstract][Full Text] [Related]
20. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
Peng X; Hu Z; Zeng L; Zhang M; Xu C; Lu B; Tao C; Chen W; Hou W; Cheng K; Bi H; Pan W; Chen J
Acta Pharm Sin B; 2024 Feb; 14(2):533-578. PubMed ID: 38322348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
